Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
11 mai 2022 08h05 HE
|
Aeterna Zentaris Inc
– Continued advancement across diversified development pipeline – Company ended the quarter with $63.6 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, May 11, 2022...
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
25 avr. 2022 08h05 HE
|
Aeterna Zentaris Inc
– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease ("PD"), a neurodegenerative movement disorder ...
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
19 avr. 2022 08h05 HE
|
Aeterna Zentaris Inc
– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO,...
Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight
12 avr. 2022 08h05 HE
|
Aeterna Zentaris Inc
– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET TORONTO, ONTARIO, April 12, 2022 ...
Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity
11 avr. 2022 08h05 HE
|
Aeterna Zentaris Inc
– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need ...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
29 mars 2022 08h00 HE
|
Aeterna Zentaris Inc
– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 ...
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
21 mars 2022 08h05 HE
|
Aeterna Zentaris Inc
– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient...
Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs
10 mars 2022 07h05 HE
|
Aeterna Zentaris Inc
– Research agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis TORONTO, ONTARIO, March 10, 2022 (GLOBE NEWSWIRE) -- Aeterna...
Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
02 mars 2022 08h05 HE
|
Aeterna Zentaris Inc
– Notice of allowance received by Company’s licensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic...
Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
07 févr. 2022 08h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...